Verrica Q2 net loss $10.2M; plans VP-102 NDA resubmission in Q1 2023

Verrica Pharmaceuticals Inc.

2022-Q2 EPS reported -$0.68 revenue$645,000

Q2 2022 net loss $10.2M ($0.37 GAAP EPS); non-GAAP net loss $8.8M ($0.32/share).
License revenue $0.2M from Torii; R&D $4.2M, G&A $5.2M.
Held Type A FDA meeting; began working with Piramal for VP-102 bulk solution.
Raised $28.5M gross in July 2022 public offering at $2.10/share.
Cash, equivalents, marketable securities, restricted cash $54.4M as of June 30, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.